Alan Cheng is a Director at the new MSD research site in South San Francisco, where he leads a group that applies advanced computational approaches towards the discovery of new medicines. Previously, he was at Amgen for 11 years, and Pfizer for 4.5 years. He has contributed to multiple clinical molecules, including four currently in clinical trials, and is an author or co-inventor on over 60 peer-reviewed publications and patent applications. He received his Ph.D. at UCSF, and his B.S and B.A. degrees at UC Berkeley. He also currently chairs the Bioinformatics M.S. program at Brandeis University.